Mariadelina Simeoni

Dr. Mariadelina Simeoni


Research Focus & Metrics

Academic Career Length

67Years (1960-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
GAGiuseppe Agapito
Giuseppe Agapito
MSMariadelina Simeoni
Mariadelina Simeoni
Barbara CalabreseBarbara Calabrese
Barbara Calabrese
ICIlaria Caré
Ilaria Caré
TLTheodora Lamprinoudi
Theodora Lamprinoudi
Mario CannataroMario Cannataro
Mario Cannataro

26 December 2023 in Genes
Verified
Journal Article
Open access
PDF file
RIRaafiah Izhar
Raafiah Izhar
MBMargherita Borriello
Margherita Borriello
ARANTONELLA LA RUSSA
ANTONELLA LA RUSSA
RPRossella Di Paola
Rossella Di Paola
ADAnanya De
Ananya De
MSMariadelina Simeoni
Mariadelina Simeoni
Fabry Disease (FD) is a rare lysosomal storage disorder caused by mutations in the GLA gene on the X chromosome, leading to a deficiency in α-galactosidase A (AGAL) enzyme activity. This leads to the accumulation of glycosphingolipids, primarily globotriaosylceramide (Gb3), in vital organs such as the kidneys, heart, and nervous system. While FD was initially considered predominantly affecting males, recent studies have uncovered that heterozygous Fabry women, carrying a single mutated GLA gene, can manifest a wide array of clinical symptoms, challenging the notion of asymptomatic carriers. The mechanisms underlying the diverse clinical manifestations in females remain not fully understood due to X-chromosome inactivation (XCI). XCI also known as “lyonization”, involves the random inactivation of one of the two X chromosomes. This process is considered a potential factor influencing phenotypic variation. This review delves into the complex landscape of FD in women, discussing its genetic basis, the available biomarkers, clinical manifestations, and the potential impact of XCI on disease severity. Additionally, it highlights the challenges faced by heterozygous Fabry women, both in terms of their disease burden and interactions with healthcare professionals. Current treatment options, including enzyme replacement therapy, are discussed, along with the need for healthcare providers to be well-informed about FD in women, ultimately contributing to improved patient care and quality of life.

25 October 2016 in Renal Failure
Verified
Journal Article
Open access
GDGiuseppina D’ONofrio
Giuseppina D’ONofrio
MSMariadelina Simeoni
Mariadelina Simeoni
PRPaolo Rizza
Paolo Rizza
MCMaria Cristina Caroleo
Maria Cristina Caroleo
MCMaria Capria
Maria Capria
GFGiorgio Fuiano
Giorgio Fuiano
Rational: Our aim was to investigate the quality of life (QoL) in 103 patients undergoing chronic hemodialysis (HD) in an integrated assessment of clinical, personological, and adaptation parameters, also in a non-urban context. Objectives: We collected data from all chronic HD patients attending four HD units. Clinical status was assessed by Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and by Age-adjusted Charlson Comorbidity Index (ACCI). Patients completed the following questionnaires: Kidney Disease Quality of Life Short Form (KDQOL-SF), Pittsburgh Sleep Quality Index (PSQI). Personality profile and coping style were assessed by Temperament and Character Inventory (TCI) revised and Coping Inventory for Stressful Situation (CISS). Data were analyzed by conventional descriptive statistics. Multiple forward stepwise linear regression analyses were performed. Main findings: Variables significantly associated with physical and mental components of KDQOL-SF were: intact parathyroid hormone (iPTH) (p = .004; p = .0015), typology of cohabitant (family member or not) (p = .022; p = .007), years of dialysis (p = .022; p = .048). Variables associated with mental component of KDQOL-SF were: PSQI (p = .000), task-coping (p = .000), avoidance-coping (p = .003), work status (p = .021). Principle conclusions: Our results suggest the importance of an integrated and multidirectional management of patients chronically undergoing HD and living in a non-urban context.

3 August 2018 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MSMariadelina Simeoni
Mariadelina Simeoni
MCMaria Lucia Citraro
Maria Lucia Citraro
ACAnnamaria Cerantonio
Annamaria Cerantonio
FDFrancesca Deodato
Francesca Deodato
Michele ProvenzanoMichele Provenzano
Michele Provenzano
GFGiorgio Fuiano
Giorgio Fuiano
Purpose Gut dysbiosis has been described in advanced, but not in initial stages of CKD. Considering the relevant impact of gut dysbiosis on renal and cardiovascular risk, its diagnosis and treatment are clinically relevant. Methods We designed, open-label, placebo-controlled intervention study (ProbiotiCKD) to evaluate gut microbiota metabolism in a cohort of KDIGO CKD patients (n = 28) at baseline and after a randomly assigned treatment with probiotics or placebo. Gut microbiota status was evaluated on:. Results Basal mean fecal Lactobacillales and Bifidobacteria concentrations were abnormally low in both groups, while urinary indican and 3-MI levels were, indicating a mixed (fermentative and putrefactive) dysbiosis. After treatment, mean fecal Lactobacillales and Bifidobacteria concentrations were increased, only in the probiotics group (p < 0.001). Conversely, mean urinary indican and 3-MI levels only in the group treated with probiotics (p < 0.001). Compared to placebo group, significant improvements of C-reactive protein (p < 0.001), iron (p < 0.001), ferritin (p < 0.001), transferrin saturation (p < 0.001), β2-microglobulin (p < 0.001), serum iPTH and serum calcium were observed only in the probiotics group. Conclusions ProbiotiCKD is the first intervention study demonstrating that an intestinal mixed dysbiosis is present even in early CKD stage and can be effectively corrected by the novel mode of administration of high-quality probiotics with improvement of inflammatory indices, iron status and iPTH stabilization.

1 June 1999 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JBJo Bowtell
Jo Bowtell
KGK. Gelly
K. Gelly
MJM. L. Jackman
M. L. Jackman
APA. Patel
A. Patel
MSMariadelina Simeoni
Mariadelina Simeoni
MRM. J. Rennie
M. J. Rennie
The purpose of this study was to determine the efficacy of glutamine in promoting whole body carbohydrate storage and muscle glycogen resynthesis during recovery from exhaustive exercise. Postabsorptive subjects completed a glycogen-depleting exercise protocol, then consumed 330 ml of one of three drinks, 18.5% (wt/vol) glucose polymer solution, 8 g glutamine in 330 ml glucose polymer solution, or 8 g glutamine in 330 ml placebo, and also received a primed constant infusion of [1-13C]glucose for 2 h. Plasma glutamine concentration was increased after consumption of the glutamine drinks (0.7–1.1 mM, P < 0.05). In the second hour of recovery, whole body nonoxidative glucose disposal was increased by 25% after consumption of glutamine in addition to the glucose polymer (4.48 ± 0.61 vs. 3.59 ± 0.18 mmol/kg, P < 0.05). Oral glutamine alone promoted storage of muscle glycogen to an extent similar to oral glucose polymer. Ingestion of glutamine and glucose polymer together promoted the storage of carbohydrate outside of skeletal muscle, the most feasible site being the liver.

13 June 2023 in Genes
Verified
Journal Article
Open access
PDF file
RPRossella Di Paola
Rossella Di Paola
ADAnanya De
Ananya De
RIRAAFIAH IZHAR
RAAFIAH IZHAR
MAMARIANNA ABATE
MARIANNA ABATE
SZSilvia Zappavigna
Silvia Zappavigna
MSMariadelina Simeoni
Mariadelina Simeoni
Chronic kidney disease (CKD) induces several systemic effects, including the accumulation and production of uremic toxins responsible for the activation of various harmful processes. Gut dysbiosis has been widely described in CKD patients, even in the early stages of the disease. The abundant discharge of urea and other waste substances into the gut favors the selection of an altered intestinal microbiota in CKD patients. The prevalence of bacteria with fermentative activity leads to the release and accumulation in the gut and in the blood of several substances, such as p-Cresol (p-C), Indoxyl Sulfate (IS) and p-Cresyl Sulfate (p-CS). Since these metabolites are normally eliminated in the urine, they tend to accumulate in the blood of CKD patients proportionally to renal impairment. P-CS, IS and p-C play a fundamental role in the activation of various pro-tumorigenic processes, such as chronic systemic inflammation, the increase in the production of free radicals and immune dysfunction. An up to two-fold increase in the incidence of colon cancer development in CKD has been reported in several studies, although the pathogenic mechanisms explaining this compelling association have not yet been described. Based on our literature review, it appears likely the hypothesis of a role of p-C, IS and p-CS in colon cancer development and progression in CKD patients.